VIROCELL_BIOLOGICS_LIMITE - Accounts


Company Registration No. 13033264 (England and Wales)
VIROCELL BIOLOGICS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED
31 DECEMBER 2021
PAGES FOR FILING WITH REGISTRAR
VIROCELL BIOLOGICS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
4 - 9
VIROCELL BIOLOGICS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2021
31 December 2021
- 1 -
2021
Notes
£
£
Fixed assets
Intangible assets
3
166,400
Tangible assets
4
56,036
222,436
Current assets
Debtors
5
107,880
Cash at bank and in hand
440,919
548,799
Creditors: amounts falling due within one year
6
(943,429)
Net current liabilities
(394,630)
Net liabilities
(172,194)
Capital and reserves
Called up share capital
7
87
Share premium account
1,999,989
Profit and loss reserves
(2,172,270)
Total equity
(172,194)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial Period from 20 November 2020 ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the Period from 20 November 2020 in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

VIROCELL BIOLOGICS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2021
31 December 2021
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 19 August 2022 and are signed on its behalf by:
Mr J W Hadden
Director
Company Registration No. 13033264
VIROCELL BIOLOGICS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
- 3 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 20 November 2020
-
-
-
-
Period ended 31 December 2021:
Loss and total comprehensive income for the period
-
-
(2,172,270)
(2,172,270)
Issue of share capital
7
87
1,999,989
-
2,000,076
Balance at 31 December 2021
87
1,999,989
(2,172,270)
(172,194)
VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
- 4 -
1
Accounting policies
Company information

Virocell Biologics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Vestry House, Laurence Pountney Hill, London, EC4 0EH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 

Revenue that has been received in relation to the sale of goods, before the significant risk and rewards of ownership of the goods have been passed to the buyer is recognised as deferred income in the balance sheet. Revenue that has been received in relation to contracts of professional services, in excess of the amount of revenue to be recognised by reference to the stage of completion is also recognised as deferred income.

 

 

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 5 -
1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
5 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment
15% straight line
Fixtures and fittings
15% straight line
Computers
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 6 -

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 7 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the Period from 20 November 2020 was:

2021
Number
Total
16
VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
- 8 -
3
Intangible fixed assets
Patents & licences
£
Cost
At 20 November 2020
-
0
Additions
208,000
At 31 December 2021
208,000
Amortisation and impairment
At 20 November 2020
-
0
Amortisation charged for the Period from 20 November 2020
41,600
At 31 December 2021
41,600
Carrying amount
At 31 December 2021
166,400
4
Tangible fixed assets
Equipment
Fixtures and fittings
Computers
Total
£
£
£
£
Cost
At 20 November 2020
-
0
-
0
-
0
-
0
Additions
3,172
3,472
67,188
73,832
At 31 December 2021
3,172
3,472
67,188
73,832
Depreciation and impairment
At 20 November 2020
-
0
-
0
-
0
-
0
Depreciation charged in the Period from 20 November 2020
476
521
16,799
17,796
At 31 December 2021
476
521
16,799
17,796
Carrying amount
At 31 December 2021
2,696
2,951
50,389
56,036
VIROCELL BIOLOGICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD FROM 20 NOVEMBER 2020 ENDED 31 DECEMBER 2021
- 9 -
5
Debtors
2021
Amounts falling due within one year:
£
Other debtors
107,880
6
Creditors: amounts falling due within one year
2021
£
Other borrowings
321,683
Trade creditors
77,663
Taxation and social security
53,187
Deferred income
427,500
Other creditors
60,902
Accruals
2,494
943,429
7
Called up share capital
2021
2021
Ordinary share capital
Number
£
Issued and fully paid
Oridnary £0.00001 shares of 0.001p each
8,661,538
87
8
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2021
£
343,400
2021-12-312020-11-20false19 August 2022CCH SoftwareCCH Accounts Production 2022.200No description of principal activityMr John W HaddenTodd C DavisJohn D EnloeDr Farzin FarzanehMr Peter E PriestleyMr Edmund G I F Truell130332642020-11-202021-12-31130332642021-12-3113033264core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2021-12-3113033264core:PlantMachinery2021-12-3113033264core:FurnitureFittings2021-12-3113033264core:ComputerEquipment2021-12-3113033264core:CurrentFinancialInstrumentscore:WithinOneYear2021-12-3113033264core:CurrentFinancialInstruments2021-12-3113033264core:ShareCapital2021-12-3113033264core:SharePremium2021-12-3113033264core:RetainedEarningsAccumulatedLosses2021-12-3113033264bus:Director12020-11-202021-12-3113033264core:RetainedEarningsAccumulatedLosses2020-11-202021-12-3113033264core:ShareCapital2020-11-202021-12-3113033264core:SharePremium2020-11-202021-12-3113033264core:IntangibleAssetsOtherThanGoodwill2020-11-202021-12-3113033264core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2020-11-202021-12-3113033264core:PlantMachinery2020-11-202021-12-3113033264core:FurnitureFittings2020-11-202021-12-3113033264core:ComputerEquipment2020-11-202021-12-3113033264core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2020-11-1913033264core:PlantMachinery2020-11-1913033264core:FurnitureFittings2020-11-1913033264core:ComputerEquipment2020-11-19130332642020-11-1913033264core:WithinOneYear2021-12-3113033264bus:PrivateLimitedCompanyLtd2020-11-202021-12-3113033264bus:SmallCompaniesRegimeForAccounts2020-11-202021-12-3113033264bus:FRS1022020-11-202021-12-3113033264bus:AuditExemptWithAccountantsReport2020-11-202021-12-3113033264bus:Director22020-11-202021-12-3113033264bus:Director32020-11-202021-12-3113033264bus:Director42020-11-202021-12-3113033264bus:Director52020-11-202021-12-3113033264bus:Director62020-11-202021-12-3113033264bus:FullAccounts2020-11-202021-12-31xbrli:purexbrli:sharesiso4217:GBP